These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 29982317)

  • 1. Next-generation sequencing technologies accelerate advances in T-cell therapy for cancer.
    Yin Q; Tang J; Zhu X
    Brief Funct Genomics; 2019 Mar; 18(2):119-128. PubMed ID: 29982317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adoptive Cell Therapy Targeting Neoantigens: A Frontier for Cancer Research.
    Wang Z; Cao YJ
    Front Immunol; 2020; 11():176. PubMed ID: 32194541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toward in silico Identification of Tumor Neoantigens in Immunotherapy.
    Zhou C; Zhu C; Liu Q
    Trends Mol Med; 2019 Nov; 25(11):980-992. PubMed ID: 31494024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Applications of Next-Generation Sequencing in Neoantigen Prediction and Cancer Vaccine Development.
    Lancaster EM; Jablons D; Kratz JR
    Genet Test Mol Biomarkers; 2020 Feb; 24(2):59-66. PubMed ID: 30907630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-throughput sequencing of the immune repertoire in oncology: Applications for clinical diagnosis, monitoring, and immunotherapies.
    Ye B; Smerin D; Gao Q; Kang C; Xiong X
    Cancer Lett; 2018 Mar; 416():42-56. PubMed ID: 29247824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Promise of Personalized TCR-Based Cellular Immunotherapy for Cancer Patients.
    Arnaud M; Bobisse S; Chiffelle J; Harari A
    Front Immunol; 2021; 12():701636. PubMed ID: 34394096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-throughput discovery of cancer-targeting TCRs.
    Bunse L; Green EW; Platten M
    Methods Enzymol; 2019; 629():401-417. PubMed ID: 31727251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Personalized T cell-mediated cancer immunotherapy: progress and challenges.
    Bethune MT; Joglekar AV
    Curr Opin Biotechnol; 2017 Dec; 48():142-152. PubMed ID: 28494274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants for Neoantigen Identification.
    Garcia-Garijo A; Fajardo CA; Gros A
    Front Immunol; 2019; 10():1392. PubMed ID: 31293573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Personalized cancer vaccines: Targeting the cancer mutanome.
    Zhang X; Sharma PK; Peter Goedegebuure S; Gillanders WE
    Vaccine; 2017 Feb; 35(7):1094-1100. PubMed ID: 27449681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination.
    Vormehr M; Schrörs B; Boegel S; Löwer M; Türeci Ö; Sahin U
    J Immunol Res; 2015; 2015():595363. PubMed ID: 26844233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Silico Prediction of Tumor Neoantigens with TIminer.
    Kirchmair A; Finotello F
    Methods Mol Biol; 2020; 2120():129-145. PubMed ID: 32124316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Links between genetics and immunology: mutations and antigens.
    Ayyoub M
    Bull Acad Natl Med; 2016 Jan; 200(1):67-79. PubMed ID: 29889414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive T-cell therapy for cancer: The era of engineered T cells.
    Bonini C; Mondino A
    Eur J Immunol; 2015 Sep; 45(9):2457-69. PubMed ID: 26202766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteogenomics offers a novel avenue in neoantigen identification for cancer immunotherapy.
    Ren Y; Yue Y; Li X; Weng S; Xu H; Liu L; Cheng Q; Luo P; Zhang T; Liu Z; Han X
    Int Immunopharmacol; 2024 Dec; 142(Pt A):113147. PubMed ID: 39270345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ProGeo-neo: a customized proteogenomic workflow for neoantigen prediction and selection.
    Li Y; Wang G; Tan X; Ouyang J; Zhang M; Song X; Liu Q; Leng Q; Chen L; Xie L
    BMC Med Genomics; 2020 Apr; 13(Suppl 5):52. PubMed ID: 32241270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of TCR β CDR3 sequencing data for tracking anti-tumor immunity.
    Zhang J; Ji Z; Smith KN
    Methods Enzymol; 2019; 629():443-464. PubMed ID: 31727253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens.
    Kiyotani K; Chan HT; Nakamura Y
    Cancer Sci; 2018 Mar; 109(3):542-549. PubMed ID: 29288513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MHC class II restricted neoantigen: A promising target in tumor immunotherapy.
    Sun Z; Chen F; Meng F; Wei J; Liu B
    Cancer Lett; 2017 Apr; 392():17-25. PubMed ID: 28104443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer Neoantigens.
    Schumacher TN; Scheper W; Kvistborg P
    Annu Rev Immunol; 2019 Apr; 37():173-200. PubMed ID: 30550719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.